Is Kyprolis + Bisantrene a perfect storm?
A proven drug that is highly cardiotoxic can be paired with Bisantrene and has demonstrated CPACS in vitro and in vivo.
The patent cliff for Kyprolis in 2027, means an evergreen ing strategy needs to be implemented yesterday. Trials would be needed and patent (which take years) need lodging ASAP.
Cipla is ready to jump in as a generic having already lost a challenge to the previous patent.
If Amgen isn’t interested, is a Dox+Bisantrene likely to to gain more traction and why?
Getting the word out direct to Pharma or industry (via scientific publication / world class conferences is a must). Has Race booked JPM2025, yet?
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-65
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
0.050(3.15%) |
Mkt cap ! $278.7M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.65 | $1.57 | $98.54K | 60.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2377 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 320 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |